Zoledronate attenuates angiotensin II-induced abdominal aortic aneurysm through inactivation of Rho/ROCK-dependent JNK and NF-κB pathway

Cardiovascular Research

Volumn 100, Issue 3, 2013, Pages 501-510

  Tsai, Shih Hung ^a,b   Huang, Po Hsun ^b,c   Peng, Yi Jen ^a   Chang, Wei Chou ^a   Tsai, Hsiao Ya ^b   Leu, Hsin Bang ^b,c   Chen, Jaw Wen ^b,c   Lin, Shing Jong ^b,c  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Abdominal aortic aneurysm; Angiotensin II; Bisphopsphonate; Low density lipoprotein receptor mice; MAPK; NF k B; Rho; Zoledronate

Indexed keywords

ANGIOTENSIN II; ELASTIN; GELATINASE A; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PLACEBO; RHO KINASE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SODIUM CHLORIDE; STRESS ACTIVATED PROTEIN KINASE; VASCULAR CELL ADHESION MOLECULE 1; ZOLEDRONIC ACID;

ABDOMINAL AORTA ANEURYSM; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENUATION; CELL ADHESION; CELL INFILTRATION; CONTROLLED STUDY; DISEASE COURSE; DOWN REGULATION; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME INACTIVATION; HUMAN; HUMAN CELL; HYPERLIPIDEMIA; IN VITRO STUDY; INCIDENCE; INTERVENTION STUDY; MACROPHAGE; MACROPHAGE MIGRATION; MALE; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; UPREGULATION; VASCULITIS;

ABDOMINAL AORTIC ANEURYSM; ANGIOTENSIN II; BISPHOPSPHONATE; LOW-DENSITY LIPOPROTEIN RECEPTOR-/- MICE; MAPK; NF-KB; RHO; ZOLEDRONATE;

ANGIOTENSIN II; ANIMALS; ANTI-INFLAMMATORY AGENTS; AORTA, ABDOMINAL; AORTIC ANEURYSM, ABDOMINAL; CELL ADHESION; CELL LINE; COCULTURE TECHNIQUES; DILATATION, PATHOLOGIC; DIPHOSPHONATES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ELASTIN; ENDOTHELIAL CELLS; ENZYME ACTIVATION; HUMANS; IMIDAZOLES; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MACROPHAGES; MALE; MATRIX METALLOPROTEINASE 2; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MONOCYTES; NF-KAPPA B; PHOSPHORYLATION; RECEPTORS, LDL; RHO GTP-BINDING PROTEINS; RHO-ASSOCIATED KINASES; RHOA GTP-BINDING PROTEIN; SIGNAL TRANSDUCTION; VASCULAR CELL ADHESION MOLECULE-1;

EID: 84887911887     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvt230     Document Type: Article

References (48)

1. Sakalihasan N, Limet R, Defawe OD Abdominal aortic aneurysm. Lancet 2005; 365: 1577-1589.
2. Trollope A, Moxon JV, Moran C.S., Golledge J Animal models of abdominal aortic aneurysm and their role in furthering management of human disease. Cardiovasc Pathol 2011; 20:114-123.
3. Scott RA, Ashton HA, Kay DN Abdominal aortic aneurysm in 4237 screened patients: prevalence, development and management over 6 years. Br J Surg 1991; 78:1122-1125.
4. Cosford PA, Leng GC Screening for abdominal aortic aneurysm. Cochrane Database Syst Rev 2007; 18:CD002945.
5. Ernst CB. Abdominal aortic aneurysm. N Engl J Med 1993; 328:1167-1172.
6. Thompson RW, Liao S, Curci JA Vascular smooth muscle cell apoptosis in abdominal aortic aneurysms. Coron Artery Dis 1997; 8:623-631.
7. Palombo D, Maione M, Cifiello B.I., Udini M., Maggio D, Lupo M. Matrix metalloprotei-nases. Their role in degenerative chronic diseases of abdominal aorta. J Cardiovasc Surg (Torino) 1999; 40:257-260.
8. Choke E, Cockerill GW, Dawson J, Wilson R.W., Jones A., Loftus IM et al. Increased angio-genesis at the site of abdominal aortic aneurysm rupture. Ann N Y Acad Sci 2006; 1085: 315-319.
9. Russell RG. Bisphosphonates: from bench to bedside. Ann N Y Acad Sci 2006; 1068: 367-401.
10. Tsai SH, Huang PH, Chang W.C., Tsai HY, Lin CP, Leu HB et al. Zoledronate inhibits ischemia-induced neovascularization by impairing the mobilization and function of endothelial progenitor cells. Plo S one 2012; 7:e41065.
11. Wu L, Zhu L, Shi W.H., Yu B., Cai D. Zoledronate inhibits intimal hyperplasia in balloon-injured rat carotid artery. Eur J Vasc Endovasc Surg 2011; 41:283-293.
12. Danenberg HD, Golomb G, Groothuis A., Gao J, Epstein H, Swaminathan RV et al. Lipo-somal alendronate inhibits systemic innate immunity and reduces in-stent neointimal hyperplasia in rabbits. Circulation 2003; 108:2798-2804.
13. Daugherty A, Cassis LA, Lu H. Complex pathologies of angiotensin II-induced abdominal aortic aneurysms. J Zhejiang Univ Sci B 2011; 12:624-628.
14. Santos LL, Cavalcanti TB, Bandeira FA Vascular effects of bisphosphonates: a systematic review. Clin Med Insights Endocrinol Diabetes 2012; 5:47-54.
15. Gozzetti A, Gennari L, Merlotti D., Salvadori S, De Paola V, Avanzati A et al. The effects of zoledronic acid on serum lipids in multiple myeloma patients. Calcif Tissue Int 2008; 82: 258-262.
16. Adami S, Braga V, Guidi G., Gatti D, Gerardi D, Fracassi E. Chronic intravenous aminobi-sphosphonate therapy increases high-density lipoprotein cholesterol and decreases low-density lipoprotein cholesterol. J Bone Miner Res 2000; 15:599-604.
17. Kanazawa I, Yamaguchi T, Hayashi K., Takase H, Shimizu T, Sugimoto T. Effects of treatment with risedronate and alfacalcidol on progression of atherosclerosis in postmeno-pausal women with type 2 diabetes mellitus accompanied with osteoporosis. Am J Med Sci 2010; 339:519-524.
18. Elmariah S, Delaney JA, O'Brien KD, Budoff MJ, Vogel-Claussen J, Fuster V et al. Bispho-sphonate use and prevalence of valvular and vascular calcification in women MESA (The Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol 2010; 56:1752-1759.
19. Celiloglu M, Aydin Y, Balci P., Kolamaz T. The effect of alendronate sodium on carotid artery intima-media thickness and lipid profile in women with postmenopausal osteoporosis. Menopause 2009; 16:689-693.
20. Montagnani A, Gonnelli S, Cepollaro C., Campagna MS, Franci MB, Pacini S et al. Changes in serum HDL and LDL cholesterol in patients with Paget's bone disease treated with pamidronate. Bone 2003; 32:15-19.
21. Daugherty A, Cassis L. Chronic angiotensin II infusion promotes atherogenesis in low density lipoprotein receptor2/2 mice. Ann N Y Acad Sci 1999; 892:108-118.
22. Daugherty A, Manning MW, Cassis LA Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest 2000; 105:1605-1612.
23. Guzeloglu M, Gul M, Reel B., Yurekli I, Aykut K, Hazan E. The effects of zoledronic acid on neointimal hyperplasia: a rabbit carotid anastomosis model. Anadolu Kardiyol Derg 2011; 11:93-100.
24. Giraudo E, Inoue M, Hanahan D. An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest 2004; 114: 623-633.
25. Morgan-Jones D., Wilkie V. Development of a leadership strategy for the Royal College of General Practitioners. Educ Prim Care 2013; 24:73-76.
26. Rateri DL, Moorleghen JJ, Balakrishnan A, Owens APIII, Howatt DA, Subramanian V et al. Endothelial cell-specific deficiency of Ang II type 1a receptors attenuates Ang II-induced ascending aortic aneurysms in LDL receptor2/2 mice. Circ Res 2011; 108:574-581.
27. Guo G, Booms P, Halushka M., Dietz HC, Ney A, Stricker S et al. Induction of macrophage chemotaxis by aortic extracts of the mg R Marfan mouse model and a Gxx PG-containing fibrillin-1 fragment. Circulation 2006; 114:1855-1862.
28. Mata KM, Prudente PS, Rocha F.S., Prado CM, Floriano EM, Elias J Jr et al. Combining two potential causes of metalloproteinase secretion causes abdominal aortic aneurysms in rats: a new experimental model. Int J Exp Pathol 2011; 92:26-39.
29. Selander KS, Monkkonen J, Karhukorpi E.K., Harkonen P., Hannuniemi R, Vaananen HK Characteristics of clodronate-induced apoptosis in osteoclasts and macrophages. Mol Pharmacol 1996; 50:1127-1138.
30. Anidjar S, Salzmann JL, Gentric D, Lagneau P., Camilleri JP, Michel JB Elastase-induced experimental aneurysms in rats. Circulation 1990; 82:973-981.
31. Yoshimura K, Aoki H, Ikeda Y., Fujii K, Akiyama N, Furutani A et al. Regression of abdominal aortic aneurysm by inhibition of c-Jun N-terminal kinase. Nat Med 2005; 11: 1330-1338.
32. Longo GM, Xiong W, Greiner T.C., Zhao Y., Fiotti N, Baxter BT Matrix metalloprotei-nases 2 and 9 work in concert to produce aortic aneurysms. J Clin Invest 2002; 110: 625-632.
33. Longo GM, Buda SJ, Fiotta N, Xiong W., Griener T, Shapiro S et al. MMP-12 has a role in abdominal aortic aneurysms in mice. Surgery 2005; 137:457-462.
34. Patel MI, Hardman DT, Fisher C.M., Appleberg M. Current views on the pathogenesis of abdominal aortic aneurysms. J Am Coll Surg 1995; 181:371-382.
35. Curci JA, Thompson RW Adaptive cellular immunity in aortic aneurysms: cause, consequence, or context? J Clin Invest 2004; 114:168-171.
36. Mong PY, Petrulio C, Kaufman H.L., Wang Q. Activation of Rho kinase by TNF-alpha is required for JNK activation in human pulmonary microvascular endothelial cells. J Immunol 2008; 180:550-558.
37. Fromigue O, Hamidouche Z, Marie PJ Blockade of the Rho A-JNK-c-Jun-MMP2 cascade by atorvastatin reduces osteosarcoma cell invasion. JBiol Chem 2008; 283:30549-30556.
38. Guo F, Tang J, Zhou Z., Dou Y, Van Lonkhuyzen D, Gao C et al. GEF-H1-Rho A signaling pathway mediates LPS-induced NF-kappa B transactivation and IL-8 synthesis in endo-thelial cells. Mol Immunol 2012; 50:98-107.
39. Jung CH, Lee WJ, Hwang J.Y., Seol SM, Kim YM, Lee YL et al. The role of Rho/Rho-kinase pathway in the expression of ICAM-1 by linoleic acid in human aortic endothelial cells. Inflammation 2012; 35:1041-1048.
40. Guo F, Zhou Z, Dou Y., Tang J, Gao C, Huan J. GEF-H1/Rho A signalling pathway mediates lipopolysaccharide-induced intercellular adhesion molecular-1 expression in endothe-lial cells via activation of p38 and NF-kappa B. Cytokine 2012; 57:417-428.
41. Wang YX, Martin-McNulty B, da Cunha V, Vincelette J, Lu X, Feng Q et al. Fasudil, a Rho-kinase inhibitor, attenuates angiotensin II-induced abdominal aortic aneurysm in apolipoprotein E-deficient mice by inhibiting apoptosis and proteolysis Circulation 2005; 111:2219-2226.
42. Li YY, Chang JW, Liu Y.C., Wang CH, Chang HJ, Tsai MC et al. Zoledronic acid induces cell-cycle prolongation in murine lung cancer cells by perturbing cyclin and Ras expression. Anticancer Drugs 2011; 22:89-98.
43. Fournier P, Boissier S, Filleur S., Guglielmi J, Cabon F, Colombel M et al. Bisphosphonates inhibit angiogenesisinvitro and testosterone-stimulated vascular regrowthinthe ventral prostate in castrated rats. Cancer Res 2002; 62:6538-6544.
44. Ylitalo R, Syvala H, Tuohimaa P., Ylitalo P. Suppression of immunoreactive macrophages in atheromatous lesions of rabbits by clodronate. Pharmacol Toxicol 2002; 90:139-143.
45. Ylitalo R, Monkkonen J, Yla-Herttuala S. Effects of liposome-encapsulated bisphosphonates on acetylated LDL metabolism, lipid accumulation and viability of phagocyting cells. Life sciences 1998; 62:413-422.
46. Nistala H, Lee-Arteaga S, Carta L., Cook JR, Smaldone S, Siciliano G et al. Differential effects of alendronate and losartan therapy on osteopenia and aortic aneurysm in mice with severe Marfan syndrome. Hum Mol Genet 2010; 19: 4790-4798.
47. Silverstein RL, Nachman RL Angiogenesis and atherosclerosis. The mandate broadens. Circulation 1999; 100:783-785.
48. Thompson MM, Jones L, Nasim A., Sayers RD, Bell PR Angiogenesis in abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 1996; 11:464-469.